Claire Flaujac

885 total citations
33 papers, 411 citations indexed

About

Claire Flaujac is a scholar working on Hematology, Internal Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Claire Flaujac has authored 33 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 12 papers in Internal Medicine and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Claire Flaujac's work include Venous Thromboembolism Diagnosis and Management (12 papers), Hemophilia Treatment and Research (10 papers) and Platelet Disorders and Treatments (9 papers). Claire Flaujac is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (12 papers), Hemophilia Treatment and Research (10 papers) and Platelet Disorders and Treatments (9 papers). Claire Flaujac collaborates with scholars based in France, Belgium and United States. Claire Flaujac's co-authors include Isabelle Gouin‐Thibault, Nadia Rosencher, Charles Marc Samama, Marie‐Hélène Horellou, Antonia Blanié, Michaëla Fontenay, Yara Rhayem, Silvy Laporte, Virginie Siguret and Xavier Delavenne and has published in prestigious journals such as Blood, Medicine and British Journal of Haematology.

In The Last Decade

Claire Flaujac

25 papers receiving 401 citations

Peers

Countries citing papers authored by Claire Flaujac

Since Specialization

Citations

This map shows the geographic impact of Claire Flaujac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Flaujac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Flaujac more than expected).

Fields of papers citing papers by Claire Flaujac

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Flaujac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Flaujac. The network helps show where Claire Flaujac may publish in the future.

Co-authorship network of co-authors of Claire Flaujac

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Flaujac. A scholar is included among the top collaborators of Claire Flaujac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Flaujac. Claire Flaujac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug‐Specific Calibration: A Solution to Reagent Variability in Extended Half‐Life Factor IX Activity Measurements 2025 ·Haemophilia ·(unknown), (unknown), Guillaume Mourey, (unknown), Valérie Eschwège, (unknown), Dominique Lasne, Sophie Voisin, Véronique Le Cam‐Duchez, (unknown), Claire Flaujac, (unknown), Cécile Lavenu‐Bombled, (unknown), Emmanuelle Jeanpierre, Magali Donnard, Claire Pouplard, Nathalie Hézard, Laurent Sattler, Christophe Nougier	0
2	Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals 2025 ·Thrombosis and Haemostasis ·Georges Jourdi, Claire Flaujac, Emmanuel de Maistre, Nicolas Gendron, Valérie Eschwège, Laëtitia Mauge, (unknown)	0
3	Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review 2024 ·Annales de biologie clinique ·(unknown), Isabelle Martin‐Toutain, (unknown), Juliette Lambert, (unknown), Fatiha Merabet, (unknown), (unknown), (unknown), P. Rousselot, Emmanuelle de Raucourt, Claire Flaujac	0
4	A focus on dominant negative variants in a series of 170 heterozygous FXI‐deficient patients 2023 ·Haemophilia ·Philippe de Mazancourt, (unknown), Claire Flaujac, Emmanuelle de Raucourt, Benoît Guillet, Frédéric Bauduer, (unknown), Philippe Beurrier, (unknown), Roseline d’Oiron, Christine Biron‐Andréani, Sandrine Meunier, Yesim Dargaud	0
5	Role of oculocerebrorenal syndrome of Lowe (OCRL) protein in megakaryocyte maturation, platelet production and functions: a study in patients with Lowe syndrome 2021 ·British Journal of Haematology ·(unknown), Dominique Lasne, Sonia Poirault‐Chassac, Tristan Mirault, Dominique Pidard, Elise Dréano, Caroline Elie, Sophie Gandrille, (unknown), Dominique Baruch, John Rendu, Julien Fauré, Claire Flaujac, Marie‐Pierre Gratacap, Piérre Siè, Pascale Gaussem, Rémi Salomon, Geneviève Baujat, Christilla Bachelot‐Loza	8
6	Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures 2021 ·Haemophilia ·Dominique Desprez, (unknown), Claire Flaujac, (unknown), Brigitte Pan‐Petesch, Philippe Beurrier, (unknown), Olivier Feugeas, (unknown), (unknown), Marc Trossaërt, Emmanuelle de Raucourt	9
7	Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT) 2020 ·European Journal Of Haematology ·Emmanuelle Jeanpierre, Claire Pouplard, Dominique Lasne, (unknown), Valérie Eschwège, Claire Flaujac, Hubert Galinat, Inès Harzallah, Valérie Proulle, (unknown), (unknown), (unknown), Pierre Toulon, Sophie Voisin, Catherine Ternisien, Christophe Nougier, (unknown)	9
8	Factor VIII assays in treated hemophilia A patients 2019 ·Annales de biologie clinique ·Dominique Lasne, Claire Pouplard, Christophe Nougier, Valérie Eschwège, (unknown), Valérie Proulle, (unknown), Inès Harzallah, Sophie Voisin, Pierre Toulon, (unknown), Hubert Galinat, Claire Flaujac, Catherine Ternisien, Emmanuelle Jeanpierre	0
9	Factor IX assays in treated hemophilia B patients 2019 ·Annales de biologie clinique ·Claire Pouplard, Emmanuelle Jeanpierre, Dominique Lasne, (unknown), Valérie Eschwège, Claire Flaujac, Hubert Galinat, Inès Harzallah, Valérie Proulle, (unknown), (unknown), Catherine Ternisien, Pierre Toulon, Sophie Voisin, Christophe Nougier	1
10	Guidelines for certification of International Normalized Ratio (INR) for vitamin K antagonists monitoring according to the EN ISO 22870 standards 2018 ·Annales de biologie clinique ·(unknown), Anne Bauters, C. Mouton, Sophie Voisin, Claire Flaujac, (unknown), Dominique Lasne	0
11	First venous thromboembolism and hormonal contraceptives in young French women 2017 ·Medicine ·Justine Hugon‐Rodin, Marie‐Hélène Horellou, Jacqueline Conard, Claire Flaujac, Anne Gompel, Geneviève Plu‐Bureau	9
12	PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban 2016 ·Annales de biologie clinique ·(unknown), (unknown), (unknown), (unknown), E. Mazoyer, Isabelle Gouin‐Thibault, Claire Flaujac	7
13	Assessment of haemostasis in patients with cirrhosis 2015 ·European Journal of Anaesthesiology ·Claude Lentschener, Claire Flaujac, (unknown), Isabelle Gouin‐Thibault, (unknown), Philippe Sogni, Charles Marc Samama	32
14	Non-VKA oral anticoagulants: an update for the clinical biologists 2015 ·Annales de biologie clinique ·François Mullier, Jonathan Douxfils, (unknown), Jean-Michel Dogné, (unknown), Claire Flaujac, Bernard Châtelain, (unknown), Meyer-Michel Samama, Isabelle Gouin‐Thibault	1
15	Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations 2015 ·Thrombosis Research ·Anne Godiér, Anne‐Céline Martin, Isabelle Leblanc, E. Mazoyer, Marie‐Hélène Horellou, (unknown), Claire Flaujac, Jean‐Louis Golmard, Nadia Rosencher, Isabelle Gouin‐Thibault	38
16	Les cliniques d’anticoagulants sont-elles efficaces en France ? Évaluation des performances de six cliniques dans la gestion des traitements par antivitamines K 2013 ·La Revue de Médecine Interne ·Jean‐Pierre Cambus, Delphine Magnin, (unknown), (unknown), (unknown), (unknown), Y. Benhamou, Claire Flaujac, MH Horellou, Emmanuelle de Raucourt, (unknown), (unknown), Virginie Siguret	8
17	Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays 2013 ·Thrombosis and Haemostasis ·Claire Flaujac, Xavier Delavenne, Sara Quenet, Marie‐Hélène Horellou, Silvy Laporte, Virginie Siguret, Thomas Lecompte, Isabelle Gouin‐Thibault	97
18	Duration of Postoperative Fibrinolysis after Total Hip or Knee Replacement: A Laboratory Follow-up Study 2012 ·Thrombosis Research ·Antonia Blanié, (unknown), Yara Rhayem, Claire Flaujac, Charles Marc Samama, Michaëla Fontenay, Nadia Rosencher	103
19	Nouveaux anticoagulants par voie orale : quelle place pour les analyses de biologie médicale ? 2011 ·Sang thrombose vaisseaux ·Isabelle Gouin‐Thibault, Patrick Mismetti, Claire Flaujac, Xavier Delavenne, Silvy Laporte, Marie‐Anne Loriot, Thomas Lecompte	5
20	Hétérogénéité pharmacologique des nouveaux anticoagulants 2011 ·Journal des Maladies Vasculaires ·(unknown), J. Conard, Claire Flaujac, S. Combe, M.H. Horellou	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact